Qube Research & Technologies (QRT)
GENB icon

Qube Research & Technologies (QRT)’s Generate Biomedicines GENB Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,221
Closed -$628K – 4243
2026
Q1 		$628K Buy
+50,221
New +$613K ﹤0.01% 2662

Other funds holding GENB

Flagship Pioneering
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Braidwell
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Arch Venture Management
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Harbourvest Partners
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Qube Research & Technologies (QRT)'s GENB Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Generate Biomedicines (GENB) in Q2 2026, closing a stake of 50,221 shares — an estimated $628K sold.

Qube Research & Technologies (QRT) first reported a position in GENB in Q1 2026 and held it in 1 quarter. The position peaked at $628K in Q1 2026. 86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining Generate Biomedicines position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 50,221 Generate Biomedicines shares in Q2 2026, an estimated $628K.
  • Qube Research & Technologies (QRT) first reported a position in Generate Biomedicines in Q1 2026 and held it in 1 quarter.
  • Qube Research & Technologies (QRT)'s Generate Biomedicines position peaked at $628K in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.